ABUS vs TRV · P/E 5.4, rev $6.2M vs P/E 14, rev $48.83B
Arbutus Biopharma Corp (ABUS) versus The Travelers Companies Inc (TRV) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
The Travelers Companies Inc (TRV) is a insurance - property & casualty company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TRV revenue for 2025-12-31 was $48.83B. Net income was $6.29B. Revenue was up 5.2% from 2024-12-31 to 2025-12-31. TRV currently screens at market cap $59.84B and trailing P/E 14.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TRV currently screens at market cap $59.84B and trailing P/E 14.4.
Not investment advice. Open the ABUS and TRV stock pages for the full models.
Not investment advice.